NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

被引：0

作者：

Vilde Drageset Haakensen

Anna K. Nowak

Espen Basmo Ellingsen

Saima Jamil Farooqi

Maria Moksnes Bjaanæs

Henrik Horndalsveen

Tine Mcculloch

Oscar Grundberg

Susana M. Cedres

Åslaug Helland

机构：

[1] Oslo University Hospital,Department of Oncology

[2] Oslo University Hospital,Department of Cancer Genetics, Institute for Cancer Research

[3] University of Western Australia,National Centre for Asbestos Related Diseases, Institute for Respiratory Health

[4] Sir Charles Gairdner Hospital,Department of Medical Oncology

[5] Oslo University Hospital,Department of Tumor Biology, Institute for Cancer Research

[6] Ultimovacs,Department of Oncology and Clinical Cancer Research Center

[7] Aalborg University Hospital,Department of Clinical Medicine, Faculty of Medicine

[8] Aalborg University,Thoracic Oncology Center, Theme Cancer

[9] Karolinska University Hospital,Oncology Department

[10] Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology,Faculty of Medicine

[11] University of Oslo,undefined

来源：

Journal of Translational Medicine | / 19卷

关键词：

Malignant pleural mesothelioma; Telomerase vaccine; Immunotherapy; hTERT; Nivolumab; Ipilimumab; Biomarker; Immune response;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] Phase II open-label study of weekly taxoprexin (TXP) as first-line treatment in patients with metastatic cutaneous and mucosal malignant melanoma
Homsi, J.
Bedikian, A. Y.
Kim, K. B.
Papadopoulos, N. E.
Hwu, W.
Mahoney, S. L.
Davies, M.
Hwu, P.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[32] Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Nathan, Paul
Ascierto, Paolo A.
Haanen, John
Espinosa, Enrique
Demidov, Lev
Garbe, Claus
Guida, Michele
Lorigan, Paul
Chiarion-Sileni, Vanna
Gogas, Helen
Maio, Michele
Fierro, Maria Teresa
Hoeller, Christoph
Terheyden, Patrick
Gutzmer, Ralf
Guren, Tormod K.
Bafaloukos, Dimitrios
Rutkowski, Piotr
Plummer, Ruth
Waterston, Ashita
Kaatz, Martin
Mandala, Mario
Marquez-Rodas, Ivan
Munoz-Couselo, Eva
Dummer, Reinhard
Grigoryeva, Elena
Young, Tina C.
Schadendorf, Dirk
EUROPEAN JOURNAL OF CANCER, 2019, 119 : 168 - 178
[33] Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study
Long, Georgina, V
Atkinson, Victoria
Lo, Serigne N.
Guminski, Alexander
Sandhu, Shahneen K.
Brown, Michael P.
Gonzalez, Maria
Mcarthur, Grant A.
Menzies, Alexander M.
LANCET ONCOLOGY, 2025, 26 (03): : 320 - 330
[34] Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
D'Angelo, Sandra P.
Mahoney, Michelle R.
Van Tine, Brian A.
Atkins, James
Milhem, Mohammed M.
Jahagirdar, Balkrishna N.
Antonescu, Cristina R.
Horvath, Elise
Tap, William D.
Schwartz, Gary K.
Streicher, Howard
LANCET ONCOLOGY, 2018, 19 (03): : 416 - 426
[35] Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Hellmann, Matthew D.
Rizvi, Naiyer A.
Goldman, Jonathan W.
Gettinger, Scott N.
Borghaei, Hossein
Brahmer, Julie R.
Ready, Neal E.
Gerber, David E.
Chow, Laura Q.
Juergens, Rosalyn A.
Shepherd, Frances A.
Laurie, Scott A.
Geese, William J.
Agrawal, Shruti
Young, Tina C.
Li, Xuemei
Antonia, Scott J.
LANCET ONCOLOGY, 2017, 18 (01): : 31 - 41
[36] A two-stage, open-label, phase II study of bortezomib plus oxaliplatin in previously treated patients with malignant pleural or peritoneal mesothelioma
Bates, Gleneara Elizabeth
Taub, Robert N.
Borczuk, Alain C.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[37] Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study
Buikhuisen, Wieneke A.
Burgers, Jacobus A.
Vincent, Andrew D.
Korse, Catharina M.
van Klaveren, Rob J.
Schramel, Franz M. N. H.
Pavlakis, Nick
Nowak, Anna K.
Custers, Frank L. J.
Schouwink, J. Hugo
Gans, Steven J. M.
Groen, Harry J. M.
Strankinga, Wim F. M.
Baas, Paul
LANCET ONCOLOGY, 2013, 14 (06): : 543 - 551
[38] An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)
Hodi, F. S.
Gibney, G.
Sullivan, R.
Sosman, J. A.
Slingluff, C. L., Jr.
Lawrence, D. P.
Logan, T. F.
Schuchter, L. M.
Nair, S.
Fecher, L.
Buchbinder, E.
Ruisi, M.
Kong, G.
Horak, C.
Weber, J. S.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S721 - S721
[39] Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Schenker, Michael
Burotto, Mauricio
Richardet, Martin
Ciuleanu, Tudor-Eliade
Goncalves, Anthony
Steeghs, Neeltje
Schoffski, Patrick
Ascierto, Paolo A.
Maio, Michele
Lugowska, Iwona
Lupinacci, Lorena
Leary, Alexandra
Delord, Jean-Pierre
Grasselli, Julieta
Tan, David S. P.
Friedmann, Jennifer
Vuky, Jacqueline
Tschaika, Marina
Konduru, Somasekhar
Vemula, Sai Vikram
Slepetis, Ruta
Kollia, Georgia
Pacius, Misena
Duong, Quyen
Huang, Ning
Doshi, Parul
Baden, Jonathan
Di Nicola, Massimo
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (08) : 1 - 11
[40] A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)
Nadja M. Meindl-Beinker
Johannes Betge
Tobias Gutting
Elke Burgermeister
Sebastian Belle
Tianzuo Zhan
Nadine Schulte
Martin Maenz
Matthias P. Ebert
Nicolai Haertel
BMC Cancer, 19

← 1 2 3 4 5 →